Redeye saw sales roughly in line with our expectations in the Q1 report, as deliveries of Carbonhand...
We cut '23e-'25e EBITA by 12-8% Some macro factors starting to ease '23e EV/EBITA at 7.
Redeye thinks that the Q1 operational update from Zwipe was softer than our expectations.
Redeye gives a brief follow-up comment on the change of focus and cost savings.
Atria reported Q1 EBIT of EUR 10.9m, 244% (EUR 7.7m) above Refinitiv consensus and 142% above our es...
Redeye updates our outlook after Q1. XVIVO’s result indicated a mix of organisational improvements a...
Redeye provides an update following Nitro Games Q1 2023 report, which showed lower revenues and cost...
Continued strong demand translates into growth and profitability New financing done, meaningful EPS ...
NAV (+0.4%) up for 11th straight quarter +24% return mainly driven by 12pp narrowing of discount NAV...
Q1 sales were c13% below our forecast, driven by weaker sales growth in Performance Chemical than we...
I Europa förbrukas ca 60 miljoner ton plast årligen, men där endast 4 % är återvunnet och resten för...
Q2 kommer vara fortsatt svårt, men vi räknar med återhämtning i H2 Den organiska tillväxten kom in p...
Redeye provides an initial comment on Carasent's shift in focus towards the Swedish market, citing "...
Q1 in line with prel. figures, no surprise Marginally lower adj.
Agilyx has announced this morning that they have entered into a strategic collaboration with BioBTX,...
5% beat on sales, 25% beat on adj. EBITA Demand remains strong, material costs decrease boosts margi...
Redeye is positive that Bioservo has registered Carbonhand as a medical-technical product according ...
EQL Pharma lämnade ett rekommenderat bud på Spotlight-bolaget Sensidose.
We make only minor estimate revisions following the Q1 report, which was in line with the preliminar...
Redeye comments on Nitro Games Q1 2023 report, which showed lower-than-expected sales but better-tha...
